<DOC>
	<DOC>NCT02805283</DOC>
	<brief_summary>The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Dapagliflozin Patient Satisfaction Survey</brief_title>
	<detailed_description>This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification. Evidence of T2D diagnosis. Age â‰¥18 as of the drug index date. 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date. Selfreported T2D diagnosis during the patient interview. Patients with evidence of type 1 diabetes mellitus and unknown type Patients who are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
</DOC>